304 related articles for article (PubMed ID: 7374415)
21. [Clinical research on the hypolipidemic action of a probucol preparation].
Naumova R; Kerekovska M; Goranov I; Balabanski L
Vutr Boles; 1986; 25(2):73-7. PubMed ID: 3716382
[TBL] [Abstract][Full Text] [Related]
22. Metabolism of plasma and biliary lipids in hyperlipoproteinaemia.
Leijd B
Acta Med Scand Suppl; 1979; 635():1-32. PubMed ID: 295570
[No Abstract] [Full Text] [Related]
23. Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
Vessby B; Lithell H; Gustafsson IB; Borberg J
Atherosclerosis; 1979 Aug; 33(4):457-77. PubMed ID: 228684
[TBL] [Abstract][Full Text] [Related]
24. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].
Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C
Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481
[TBL] [Abstract][Full Text] [Related]
25. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
Lopez Rodriguez J; Martorell J
Clin Ther; 1980; 3(4):234-41. PubMed ID: 7273061
[TBL] [Abstract][Full Text] [Related]
26. [Longterm therapy and etofibrate (author's transl)].
Kaffarnik H; Schneider J; Schubotz R; Zöfel P
MMW Munch Med Wochenschr; 1980 Jan; 122(3):95-8. PubMed ID: 6767931
[TBL] [Abstract][Full Text] [Related]
27. [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)].
Schneider J; Mühlfellner G; Mühlfellner O; Hausmann L; Schubotz R
Arzneimittelforschung; 1980; 30(11b):2059-62. PubMed ID: 7194060
[TBL] [Abstract][Full Text] [Related]
28. Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
Domingo AJ; Gutiérrez JA; Menéndez JA; Micó L; Muñoz M; de Oya M
Clin Ther; 1980; 3(3):219-26. PubMed ID: 7459931
[TBL] [Abstract][Full Text] [Related]
29. [The problem of type changes in hyperlipoproteinemia (type IIb, IV, V) under clofibrate and m-inositol nicotinate therapy].
Schwartzkopff W; Zschiedrich M
Verh Dtsch Ges Inn Med; 1976; 82 Pt 1():825-9. PubMed ID: 196436
[No Abstract] [Full Text] [Related]
30. [The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa (author's transl)].
Mertz DP; Loewer H; Suermann I
Med Klin; 1979 Dec; 74(51-52):1953-6. PubMed ID: 542179
[TBL] [Abstract][Full Text] [Related]
31. [Effect of phenofibrate on the blood serum lipid level in hyperlipoproteinemias and its comparison with clofibrate].
Sznajderman M
Pol Arch Med Wewn; 1980 Jun; 63(6):543-9. PubMed ID: 7402954
[No Abstract] [Full Text] [Related]
32. [Evaluation of apoproteins A and B, lipoproteins and plasma lipids during treatment with bezafibrate in various forms of hyperlipoproteinemia].
Saitta A; Bonaiuto M; Lanzafame F; Mileto A; Pernice F; Cinquegrani M; Mazza G; Micali G; Pangallo A; Fodale P
Clin Ter; 1988 Mar; 124(5):373-81. PubMed ID: 2974348
[No Abstract] [Full Text] [Related]
33. [Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb].
Kokot F; Szczechowska E
Z Gesamte Inn Med; 1981 Jul; 36(13):454-7. PubMed ID: 7025475
[TBL] [Abstract][Full Text] [Related]
34. [Effect of a new synthetic compound (3-nicotinoyl-oxypropyl p-chlorophenoxy isobutyrate: I.612) on plasma lipids in patients with type IIa, IIb and IV hyperdyslipidemia].
Bucalossi A; Buzzelli G; D'Alessandro A
Clin Ter; 1979 Apr; 89(2):127-49. PubMed ID: 226307
[No Abstract] [Full Text] [Related]
35. Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Olsson AG; Orö L
Atherosclerosis; 1982 Apr; 42(2-3):229-43. PubMed ID: 6951582
[TBL] [Abstract][Full Text] [Related]
36. [Clinical study with a new antihyperlipemic combination].
Pistautz H
Arzneimittelforschung; 1977; 27(1):152-6. PubMed ID: 576816
[TBL] [Abstract][Full Text] [Related]
37. [Effect of combination therapy of clofibric acid and nicotinic acid derivatives on fatty acid metabolism in hyperlipoproteinemia].
Reuter W
Z Gesamte Inn Med; 1982 Oct; 37(20):682-8. PubMed ID: 6818779
[TBL] [Abstract][Full Text] [Related]
38. [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
Altomonte L; Mingrone G; Ghirlanda G; Manna R; Rebuzzi A; Pala MA; Greco AV
Minerva Med; 1980 Feb; 71(4):273-8. PubMed ID: 7354946
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of primary hyperlipoproteinemias of type IIB and IV with butylbiguanide and clofibrate (author's transl)].
Koschinsky T; Gries FA; Schwandt P; Weisweiler P; Hansen W; Nijssen J; Beckmann R
MMW Munch Med Wochenschr; 1977 May; 119(20):701-4. PubMed ID: 195201
[TBL] [Abstract][Full Text] [Related]
40. [Lowering of the lipoproteins in type IIa hyperlipoproteinemia by means of bezafibrate. Comparison with clofibrate].
Mertz DP; Suermann I; Loewer H
MMW Munch Med Wochenschr; 1979 Oct; 121(40):1295-6. PubMed ID: 226879
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
